Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting ...

Rein Therapeutics initiates RENEW phase 2 trial of LTI-03 in patients with idiopathic pulmonary fibrosis: Austin, Texas Tuesday, May 13, 2025, 18:00 Hrs [IST] Rein Therapeutics (R ...

Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial, assessing LTI-03 as a potential ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed ...

Credit: SkazovD / Shutterstock. Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting idiopathic pulmonary fibrosis (IPF), with ...

The Center for AIDS Health Disparities Research (P.P., R.C., G.M., M.B., C.D.), Meharry Medical College, Nashville, TN. Department of Microbiology, Immunology, and ...